PrismDx

Avoid taking drugs that don’t work.

Breaking the law of averages

Therapies are developed for the “average” patient, even though there is no such thing. Scipher is breaking this law of averages to ensure patients get the right treatment from day one.

Predicting Drug Response to the Expensive Targeted Therapies

Our diagnostic tests identify patients who will not respond to a specific targeted drug so they can be prescribed an alternative treatment. As autoimmune diseases are progressive, time is invaluable to the patient.  

Sample

Our tests require a small blood or tissue sample from the patient

Analyze

RNA is extracted from the sample and analyzed

Result

The test determines if the patient’s RNA profile is a better match to a “responder” or “non-responder”.

Tumor Necrosis Factor inhibitors (anti-TNFs) are the world’s largest selling drugs in the world however only about 34% of patients with rheumatoid arthritis (RA) respond adequately to them.

PrismRA

PrismRA identifies rheumatoid arthritis patients who will not respond to anti-TNFs

PrismUC

PrismUC predicts non-response to anti-TNFs for patients with ulcerative colitis

Both tests have been shown to identify at least half of patients who will not respond to anti-TNFs with at least 90% accuracy, performance requirements set by rheumatologists and gastroenterologists.

Join a Clinical Trial

We are recruiting US-based sites and patients to participate in our prospective trials for our diagnostic tests
Learn More

Product Pipeline

Through our diagnostics tests and drug targets, we are advancing precision medicine in autoimmune diseases
Learn More